Erratum: Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates (Molecular Therapy (2009) 17 (1804-1813) DOI: 10.1038/mt.2009.165);Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates

Molecular Therapy

Volumn 17, Issue 10, 2009, Pages 1804-1813

  Dharmapuri, Sridhar ^a   Peruzzi, Daniela ^a   Mennuni, Carmela ^a   Calvaruso, Francesco ^a   Giampaoli, Saverio ^a   Barbato, Gaetano ^a   Kandimalla, Ekambar R ^b   Agrawal, Sudhir ^b   Scarselli, Elisa ^a   Mesiti, Giuseppe ^a   Ciliberto, Gennaro ^a   La Monica, Nicola ^a   Aurisicchio, Luigi ^a  

^a IRBM   (Italy)

^b HYBRIDON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; CANCER VACCINE; EPITOPE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOMODULATORY OLIGONUCLEOTIDE; INTERLEUKIN 12; INTERLEUKIN 6; PLASMID DNA; TELOMERASE REVERSE TRANSCRIPTASE; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SCREENING; ELECTROPORATION; GENETIC IMMUNIZATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; MONOTHERAPY; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; RHESUS MONKEY;

ADENOVIRIDAE; ANIMALIA; MACACA MULATTA; PRIMATES;

EID: 70349861889     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.276     Document Type: Erratum

References (49)

1. Meyerson, M, Counter, CM, Eaton, EN, Ellisen, LW, Steiner, P, Caddle, SD et al. (1997). hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785-795.
2. Nakamura, TM, Morin, GB, Chapman, KB, Weinrich, SL, Andrews, WH, Lingner, J et al. (1997). Telomerase catalytic subunit homologs from fission yeast and human. Science 277: 955-959.
3. Kim, NW, Piatyszek, MA, Prowse, KR, Harley, CB, West, MD, Ho, PL et al. (1994). Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015.
4. Prud'homme, GJ (2005). DNA vaccination against tumors. J Gene Med 7: 3-17.
5. Babiuk, S, Baca-Estrada, ME, Foldvari, M, Storms, M, Rabussay, D, Widera, G et al. (2002). Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 20: 3399-3408.
6. Aurisicchio, L, Mennuni, C, Giannetti, P, Calvaruso, F, Nuzzo, M, Cipriani, B et al. (2007). Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int J Cancer 120: 2290-2300.
7. Scheerlinck, JP, Karlis, J, Tjelle, TE, Presidente, PJ, Mathiesen, I and Newton, SE (2004). In vivo electroporation improves immune responses to DNA vaccination in sheep. Vaccine 22: 1820-1825.
8. Shiver, JW, Fu, TM, Chen, L, Casimiro, DR, Davies, ME, Evans, RK et al. (2002). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
9. Yang, ZY, Wyatt, LS, Kong, WP, Moodie, Z, Moss, B and Nabel, GJ (2003). Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 77: 799-803.
10. Casimiro, DR, Bett, AJ, Fu, TM, Davies, ME, Tang, A, Wilson, KA et al. (2004). Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 78: 11434-11438.
11. Iwasaki, A and Medzhitov, R (2004). Toll-like receptor control of the adaptive immune responses. Nat Immunol 5: 987-995.
12. Krieg, AM (2008). Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27: 161-167.
13. Ballas, ZK (2007). Modulation of NK cell activity by CpG oligodeoxynucleotides. Immunol Res 39: 15-21.
14. He, B, Qiao, X and Cerutti, A (2004). CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 173: 4479-4491.
15. Krieg, AM, Yi, AK, Matson, S, Waldschmidt, TJ, Bishop, GA, Teasdale, R et al. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.
16. Yi, AK, Chang, M, Peckham, DW, Krieg, AM and Ashman, RF (1998). CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol 160: 5898-5906.
17. Kandimalla, ER, Bhagat, L, Cong, YP, Pandey, RK, Yu, D, Zhao, Q et al. (2003). Secondary structures in CpG oligonucleotides affect immunostimulatory activity. Biochem Biophys Res Commun 306: 948-953.
18. Kandimalla, ER, Bhagat, L, Li, Y, Yu, D, Wang, D, Cong, YP et al. (2005). Immunomodulatory oligonucleotides containing a cytosine-phosphate-2′-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists. Proc Natl Acad Sci USA 102: 6925-6930.
19. Kandimalla, ER, Bhagat, L, Yu, D, Cong, Y, Tang, J and Agrawal, S (2002). Conjugation of ligands at the 5′-end of CpG DNA affects immunostimulatory activity. Bioconjug Chem 13: 966-974.
20. Kandimalla, ER, Bhagat, L, Zhu, FG, Yu, D, Cong, YP, Wang, D et al. (2003). A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc Natl Acad Sci USA 100: 14303-14308.
21. Wang, D, Kandimalla, ER, Yu, D, Tang, JX and Agrawal, S (2005). Oral administration of second-generation immunomodulatory oligonucleotides induces mucosal Th1 immune responses and adjuvant activity. Vaccine 23: 2614-2622.
22. Yu, D, Kandimalla, ER, Bhagat, L, Tang, JY, Cong, Y, Tang, J et al. (2002). 'Immunomers' - novel 3′-3′-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res 30: 4460-4469.
23. Wang, H, Rayburn, ER, Wang, W, Kandimalla, ER, Agrawal, S and Zhang, R (2006). Immunomodulatory oligonucleotides as novel therapy for breast cancer: Pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther 5: 2106-2114.
24. Wang, H, Rayburn, ER, Wang, W, Kandimalla, ER, Agrawal, S and Zhang, R (2006). Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther 5: 1585-1592.
25. Damiano, V, Caputo, R, Garofalo, S, Bianco, R, Rosa, R, Merola, G et al. (2007). TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci USA 104: 12468-12473.
26. Aurisicchio, L, Peruzzi, D, Conforti, A, Dharmapuri, S, Biondo, A, Giampaoli, S et al. (2009). Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin Cancer Res 15: 1575-1584.
27. Moore, DJ, Hwang, J, McGreivy, J, Park, S, Malik, S, Martin, RR et al. (2005). Phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors. J Clin Oncol 23 (suppl.): 2503.
28. Hwang, JJ, Park, S, Amin, A, Martin, RR, Sullivan, T, Burns, T et al. (2004). A phase I study of HYB2055 in patients (pts) with advanced solid malignancies. J Clin Oncol 22 (suppl.): 3111.
29. Krieg, AM, Efler, SM, Wittpoth, M, Al Adhami, MJ and Davis, HL (2004). Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 27: 460-471.
30. + T lymphocytes in rhesus macaques. J Immunol Methods 325: 20-34.
31. Harley, CB (2008). Telomerase and cancer therapeutics. Nat Rev Cancer 8: 167-179.
32. Vonderheide, RH (2007). Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention. Discov Med 7: 103-108.
33. Chen, DY, Vance, BA, Thompson, LB, Domchek, SM and Vonderheide, RH (2007). Differential lysis of tumors by polyclonal T cell lines and T cell clones specific for hTERT. Cancer Biol Ther 6: 1991-1996.
34. + T cell responses in patients with metastatic prostate cancer. J Immunol 174: 3798-3807.
35. Domchek, SM, Recio, A, Mick, R, Clark, CE, Carpenter, EL, Fox, KR et al. (2007). Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res 67: 10546-10555.
36. Mennuni, C, Ugel, S, Mori, F, Cipriani, B, Iezzi, M, Pannellini, T et al. (2008). Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res 68: 9865-9874.
37. Fattori, E, Aurisicchio, L, Zampaglione, I, Arcuri, M, Cappelletti, M, Cipriani, B et al. (2009). Her2/neu genetic cancer vaccine in non human primates: Relevance of single nucleotide polymorphisms. Hum Gene Ther 20: 253-265.
38. + T-cell reactivity in melanoma patients. Clin Cancer Res 14: 4532-4542.
39. Pashenkov, M, Goëss, G, Wagner, C, Hörmann, M, Jandl, T, Moser, A et al. (2006). Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 24: 5716-5724.
40. Kwissa, M, Amara, RR, Robinson, HL, Moss, B, Alkan, S, Jabbar, A et al. (2007). Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med 204: 2733-2746.
41. Cho, HI, Niu, G, Bradley, N and Celis, E (2008). Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors. Cancer Immunol Immunother 57: 1695-1703.
42. Wille-Reece, U, Flynn, BJ, Loré, K, Koup, RA, Miles, AP, Saul, A et al. (2006). Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 203: 1249-1258.
43. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115: 739-746.
44. + T cells in melanoma patients. J Immunother 31: 781-791.
45. Uccellini, MB, Busconi, L, Green, NM, Busto, P, Christensen, SR, Shlomchik, MJ et al. (2008). Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-alpha. J Immunol 181: 5875-5884.
46. Bernasconi, NL, Onai, N and Lanzavecchia, A (2003). A role for toll-like receptors in acquired immunity: Up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 101: 4500-4504.
47. Masutomi, K, Kaneko, S, Yasukawa, M, Arai, K, Murakami, S and Kobayashi, K (2002). Identification of serum anti-human telomerase reverse transcriptase (hTERT) auto-antibodies during progression to hepatocellular carcinoma. Oncogene 21: 5946-5950.
48. Facciabene, A, Aurisicchio, L, Elia, L, Palombo, F, Mennuni, C, Ciliberto, G et al. (2007). Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects. Vaccine 26: 47-58.
49. Mennuni, C, Calvaruso, F, Facciabene, A, Aurisicchio, L, Storto, M, Scarselli, E et al. (2005). Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer 117: 444-455.